📊 OCUL Key Takeaways
Is Ocular Therapeutix, Inc. (OCUL) a Good Investment?
Ocular Therapeutix is a pre-profitable biotech company with critically low revenue of $10.8M that is declining 18.5% YoY, combined with severe operating losses exceeding $93M annually. While the $666.7M cash position provides substantial runway (~9.4 years at current burn), the inability to generate meaningful revenue growth and the $70.7M annual free cash flow burn raise fundamental questions about business viability.
OCULAR THERAPEUTIX has a strong, low-leverage balance sheet with ~$737M in cash and very high liquidity, providing a multi-year runway. However, fundamentals are weak: revenue declined 18.5% YoY and margins are extremely negative, driving heavy operating and free-cash-flow losses. Until revenue re-accelerates and operating losses compress materially, the risk-reward on fundamentals remains unfavorable.
Ocular Therapeutix, Inc. Key Strengths (OCUL)
- Fortress balance sheet with $666.7M cash and minimal leverage (D/E 0.04x)
- Exceptional liquidity position with 14.81x current ratio reducing bankruptcy risk
- 9+ year cash runway at current burn rate provides time for product commercialization
- Exceptional liquidity (current ratio ~15x; cash ~$737M) provides runway
- Minimal leverage (D/E ~0.04x) reduces solvency risk
- Large equity base relative to liabilities supports resilience
OCUL Stock Risks: Ocular Therapeutix, Inc. Investment Risks
- Revenue declining 18.5% YoY from minimal $10.8M base indicates failed commercialization trajectory
- Operating losses of $93.3M against $10.8M revenue (-865.5% margin) demonstrates broken unit economics
- Annual free cash burn of $70.7M is unsustainable without significant revenue growth or cost restructuring
- Severe and persistent losses (operating margin ~-520%, FCF margin ~-418%)
- Revenue contraction (-18.5% YoY) signals weak commercial traction
- Sustained cash burn could lead to future dilution once runway shortens
Key Metrics to Watch
- Revenue trend reversal - must demonstrate YoY growth within next 2-3 quarters
- Operating cash burn rate - any acceleration would threaten runway; improvement critical
- Product pipeline advancement and clinical trial outcomes for future revenue drivers
- Revenue growth trajectory (quarterly YoY/seq)
- Operating cash burn and operating margin improvement
Ocular Therapeutix, Inc. (OCUL) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 14.81x current ratio provides a solid financial cushion.
OCUL Profit Margin, ROE & Profitability Analysis
OCUL vs Healthcare Sector: How Ocular Therapeutix, Inc. Compares
How Ocular Therapeutix, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Ocular Therapeutix, Inc. Stock Overvalued? OCUL Valuation Analysis 2026
Based on fundamental analysis, Ocular Therapeutix, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Ocular Therapeutix, Inc. Balance Sheet: OCUL Debt, Cash & Liquidity
OCUL Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Ocular Therapeutix, Inc.'s revenue has grown significantly by 46% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.02 indicates the company is currently unprofitable.
OCUL Revenue Growth, EPS Growth & YoY Performance
OCUL Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $10.7M | -$64.1M | $-0.38 |
| Q3 2025 | $14.5M | -$36.5M | $-0.22 |
| Q2 2025 | $13.5M | -$43.8M | $-0.26 |
| Q1 2025 | $10.7M | -$64.1M | $-0.38 |
| Q3 2024 | $15.1M | -$516.0K | $-0.22 |
| Q2 2024 | $15.2M | -$20.7M | $-0.26 |
| Q1 2024 | $13.4M | -$30.3M | $-0.39 |
| Q3 2023 | $12.0M | -$516.0K | $-0.25 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Ocular Therapeutix, Inc. Dividends, Buybacks & Capital Allocation
OCUL SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Ocular Therapeutix, Inc. (CIK: 0001393434)
📋 Recent SEC Filings
❓ Frequently Asked Questions about OCUL
What is the AI rating for OCUL?
Ocular Therapeutix, Inc. (OCUL) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 71% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are OCUL's key strengths?
Claude: Fortress balance sheet with $666.7M cash and minimal leverage (D/E 0.04x). Exceptional liquidity position with 14.81x current ratio reducing bankruptcy risk. ChatGPT: Exceptional liquidity (current ratio ~15x; cash ~$737M) provides runway. Minimal leverage (D/E ~0.04x) reduces solvency risk.
What are the risks of investing in OCUL?
Claude: Revenue declining 18.5% YoY from minimal $10.8M base indicates failed commercialization trajectory. Operating losses of $93.3M against $10.8M revenue (-865.5% margin) demonstrates broken unit economics. ChatGPT: Severe and persistent losses (operating margin ~-520%, FCF margin ~-418%). Revenue contraction (-18.5% YoY) signals weak commercial traction.
What is OCUL's revenue and growth?
Ocular Therapeutix, Inc. reported revenue of $10.8M.
Does OCUL pay dividends?
Ocular Therapeutix, Inc. does not currently pay dividends.
Where can I find OCUL SEC filings?
Official SEC filings for Ocular Therapeutix, Inc. (CIK: 0001393434) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is OCUL's EPS?
Ocular Therapeutix, Inc. has a diluted EPS of $-0.40.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is OCUL's fundamental grade?
Based on our AI fundamental analysis in May 2026, Ocular Therapeutix, Inc. has a C grade with 71% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is OCUL stock overvalued or undervalued?
Valuation metrics for OCUL: ROE of -15.2% (sector avg: 15%), net margin of -821.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is OCUL's AI grade for 2026?
Our dual AI analysis gives Ocular Therapeutix, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is OCUL's free cash flow?
Ocular Therapeutix, Inc.'s operating cash flow is $-66.0M, with capital expenditures of $4.7M. FCF margin is -655.1%.
How does OCUL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -821.6% (avg: 12%), ROE -15.2% (avg: 15%), current ratio 14.81 (avg: 2).